Infliximab receives 13th approval
Anti-TNF therapy infliximab (Remicade, Centocor) is now approved for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy.
Anti-TNF therapy infliximab (Remicade, Centocor) is now approved for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy. The FDA nod marks the 13th indication approved for the drug. In EXPRESS, a phase III clinical trial, eight out of 10 patients receiving induction therapy achieved a 75% improvement in their psoriasis by week 10. Remicade is also approved to treat inflammatory diseases in gastroenterology, dermatology, and rheumatology.
Recent Videos
Related Content
